Moderna develops mRNA vaccine against norovirus
Av Moderna, known for its COVID-19 vaccine, has made significant progress with a new mRNA vaccine against this unpleasant disease. The company has recruited 25,000 participants for a study expected to last two years, writes Svenska Dagbladet.
"The fact that they have come this far shows that the results from previous studies have been promising. It is an important milestone," says Elin Esbjörner, Associate Professor of Chemical Biology at Chalmers, to the newspaper.
The goal is to be able to submit an application for marketing authorization in 2026, and then, if all goes well, have an approved vaccine the following year.
Norovirus
Norovirus is a major cause of vomiting and diarrhea, and foodborne illness.
Symptoms can include sudden nausea, stomach pain, feeling tired or weak, muscle pains, and fever.
These symptoms, often known as acute gastroenteritis (AGE), generally last for 1 to 3 days. In severe cases, these symptoms can lead to dehydration, which may require hospitalization or IV fluids.
Norovirus spreads quickly through interactions in places like day care centers, retirement communities, cruise ships, and restaurants. Children under age 5, adults over age 60, and people with underlying health conditions are at greater risk of serious symptoms of norovirus.
Source: Moderna
Artikeln är en del av vårt tema om News in English.